Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Temigal
- Development stage
- Phase 4
- Lead developer
- Provident Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Temigal is a fixed-dose combination of sacubitril and valsartan developed by Provident Pharmaceuticals. It is a generic version of Entresto, which belongs to the class of angiotensin receptor-neprilysin inhibitors (ARNIs). Sacubitril is a prodrug that is metabolized in vivo to the active neprilysin inhibitor sacubitrilat (LBQ657), which prevents the degradation of natriuretic peptides (such as atrial natriuretic peptide [ANP] and brain natriuretic peptide [BNP]), thereby promoting vasodilation, natriuresis, and diuresis. Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the angiotensin II type-1 (AT1) receptor, inhibiting the renin-angiotensin-aldosterone system (RAAS) to prevent vasoconstriction, aldosterone release, and cardiac remodeling. Temigal is formulated as film-coated tablets in strengths of 24+26 mg, 49+51 mg, and 97+103 mg, and is indicated for the treatment of chronic heart failure and essential hypertension.
- Brand names
- Temigal
- Other names
- sacubitril + valsartansacubitril-valsartansacubitril/valsartan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)NEP (Neutral Endopeptidase)
Beyond the preview
Go deeper on Temigal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Temigal.